for the treatment of hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome (PWS). Soleno expects VYKAT XR to be available in the U.S. beginning in April 2025.

Distinctive facial features also identify a child with Prader-Willi syndrome. These include a narrow face, almond-shaped eyes, small-appearing mouth, a thin upper lip with downturned corners of ...

The US Food and Drug Administration (FDA) has approved Soleno Therapeutics’ (Nasdaq: SLNO) Vykat (diazoxide choline) extended ...

Mark Allepuz-Rico was just three weeks old when his family were told the 'devastating' news about Prader-Willi syndrome ...

Nine-year-old Mark Allepuz-Rico was just three weeks old when his family were told the "devastating" news that he suffers from Prader-Willi syndrome - a disorder which means he needs five meals a day.

Distinctive facial features also identify a child with Prader-Willi syndrome. These include a narrow face, almond-shaped eyes, small-appearing mouth, a thin upper lip with downturned corners of the ...

The BP1-BP5 segment includes the Prader-Willi Syndrome (PWS) and the Angelman Syndrome (AS ... growth and development, (2) dysmorphic features, (3) intelligence and academic achievement, (4) ...

The FDA has approved the first therapy to address hyperphagia for children and adults aged 4 years and older with ...

The Food and Drug Administration (FDA) has approved Vykat™ XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...